Safety and immunogenicity of one or two doses of the rVSVΔG-ZEBOV-GP Ebola virus vaccine in adults and adolescents living with HIV: a phase 2, multicentre, double-blind, randomised, placebo-controlled trial

The Lancet HIV · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles